Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Longitude Capital on the deal.
Longitude Capital, a leading healthcare venture capital firm, announced its closing of Longitude Venture Partners IV, L.P., with $585 million in capital commitments. LVP4, the largest fund that Longitude Capital has raised to date, will build on the proven strategy of its predecessor funds by investing in biotechnology, medical technology, and health solutions companies that seek to transform the healthcare industry.
LVP4 will invest opportunistically across all stages of a company’s development through a variety of approaches that include traditional venture capital investing and special situations such as spin-outs, equity-linked transactions, and private investments in public equities. Many of these investments stem from Longitude’s proprietary research of targeted healthcare sectors, therapeutic areas, and technologies of interest.
The Gunderson deal team was led by Malcolm Nicholls (Picture) and included Brian Huber, Andrew Fink, Bayard Dodge, Sujata Awasthi and David Myerson.
Involved fees earner: Sujata Awasthi – Gunderson Dettmer; Bayard Dodge – Gunderson Dettmer; Andrew Fink – Gunderson Dettmer; Brian Huber – Gunderson Dettmer; David Myerson – Gunderson Dettmer; Malcolm Nicholls – Gunderson Dettmer;
Law Firms: Gunderson Dettmer;
Clients: Longitude Capital Management Co LLC;